TM4SF20

TM4SF20 is an ER-resident polytopic membrane protein that functions as a ceramide-responsive switch controlling regulated intramembrane proteolysis (RIP) of the transcription factor CREB3L1, thereby linking lipid signaling to collagen synthesis and chemotherapy responses. In the absence of ceramide, TM4SF20 adopts a TRAM2-dependent topology with its N terminus translocated into the ER lumen and undergoes post-translational retrotranslocation of a glycosylated luminal loop (N163 region), functioning as an inhibitor of CREB3L1 cleavage; TGF-β promotes collagen synthesis by downregulating TM4SF20 expression and relieving this inhibition (PMID:25310401, PMID:36972171). Ceramide inverts TM4SF20 membrane topology through Regulated Alternative Translocation (RAT) of its first transmembrane helix—dependent on a critical GXXXN motif residue Asn-26—converting TM4SF20 from an inhibitor to an activator of CREB3L1 proteolytic activation, a mechanism also required for doxorubicin chemosensitivity (PMID:27499293, PMID:30808712, PMID:32986129). Loss of exon 3 produces a truncated protein that fails to reach the membrane and accumulates in the cytoplasm, linking TM4SF20 to a language delay phenotype in affected families (PMID:23810381).

1. 2013 Medium

   It was unknown whether TM4SF20 required intact membrane targeting for function; a disease-associated exon 3 deletion was shown to produce a truncated protein that mislocalizes to the cytoplasm, establishing that proper membrane insertion is essential.

   Evidence Minigene analysis and subcellular localization of truncated vs. wild-type TM4SF20 in transfected cells

   PMID:23810381

   Open questions at the time

   • Single-lab observation without independent replication
   • Whether cytoplasmic accumulation causes a dominant-negative effect or simple loss of function was not determined
   • Downstream cellular consequences of mislocalization were not characterized
2. 2014 High

   The molecular function of TM4SF20 was unknown; loss-of-function and expression studies revealed that TM4SF20 normally inhibits regulated intramembrane proteolysis of CREB3L1, and TGF-β stimulates collagen synthesis by downregulating TM4SF20 to release this inhibition.

   Evidence Knockdown, overexpression, CREB3L1 proteolytic activation, and nuclear translocation assays in A549 cells

   PMID:25310401

   Open questions at the time

   • The mechanism by which TM4SF20 inhibits CREB3L1 cleavage (direct interaction vs. indirect) was not resolved
   • Whether CREB3L1 is the sole downstream target was not tested
3. 2016 High

   How ceramide signaling could toggle TM4SF20 activity was unknown; topology mapping and TRAM2 dependence experiments demonstrated that ceramide inverts TM4SF20 membrane topology via Regulated Alternative Translocation (RAT), converting it from an inhibitor to an activator of CREB3L1 cleavage.

   Evidence Topology mapping, co-immunoprecipitation with TRAM2, TRAM2 knockdown, and ceramide treatment with CREB3L1 cleavage readout

   PMID:27499293

   Open questions at the time

   • How ceramide is sensed at the translocon to alter translocation directionality was not identified
   • Whether other lipids can similarly trigger RAT was not explored
4. 2019 High

   The structural determinants within TM4SF20 that sense ceramide during RAT were unknown; systematic mutagenesis identified Asn-26 in a GXXXN motif and an adjacent Pro-29/Leu-25/Val-17 surface on the first transmembrane helix as essential for ceramide-responsive topology inversion.

   Evidence Site-directed mutagenesis, TM4SF20-TM4SF40 chimera swaps, topology and CREB3L1 cleavage assays

   PMID:30808712

   Open questions at the time

   • The translocon-side partner that reads these residues during RAT is unidentified
   • No structural model of the TM1–translocon interaction exists
   • Whether these residues directly contact ceramide or a ceramide-modified protein is unknown
5. 2021 Medium

   Whether RAT of TM4SF20 had physiological consequences beyond collagen regulation was unclear; RAT-deficient mutants showed that ceramide-induced topology switching is required for doxorubicin chemosensitivity.

   Evidence Cell-based chemotherapy response assays with RAT-deficient TM4SF20 mutants

   PMID:32986129

   Open questions at the time

   • Limited methodological detail in the reporting context
   • In vivo validation of the chemotherapy connection is lacking
   • Whether RAT affects sensitivity to other ceramide-generating chemotherapeutics is untested
6. 2023 High

   Post-translational topology remodeling of TM4SF20 beyond initial RAT was uncharacterized; glycosylation mapping revealed that a luminal loop glycosylated at N132/N148/N163 undergoes ERAD-independent retrotranslocation to the cytosol, and ceramide delays this second topology rearrangement.

   Evidence N-glycosylation site mapping, topology assays, ERAD inhibitor controls, ceramide treatment, biochemical fractionation

   PMID:36972171

   Open questions at the time

   • The machinery mediating ERAD-independent retrotranslocation is unidentified
   • Whether retrotranslocation is required for the inhibitory function of TM4SF20 has not been directly tested
   • The fate of the deglycosylated retrotranslocated loop is unknown

• The identity of the translocon component(s) that read ceramide levels and the TM1 GXXXN motif to execute RAT, and the structural basis of TM4SF20's dual topology, remain unresolved.
• No cryo-EM or crosslinking-MS structure of TM4SF20 at the translocon
• Direct ceramide-binding partner at the translocon not identified
• In vivo physiological roles beyond cell-based assays not established